BAM
NKTR icon

Blueshift Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Blueshift Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,228
Closed -$452K – 1034
2021
Q4 		$452K Buy
+2,228
New +$483K 0.04% 510

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Blueshift Asset Management's NKTR Position: Q1 2022 in Review

Blueshift Asset Management sold out of Nektar Therapeutics (NKTR) in Q1 2022, closing a stake of 2,228 shares — an estimated $452K sold.

Blueshift Asset Management first reported a position in NKTR in Q4 2021 and held it in 1 quarter. The position peaked at $452K in Q4 2021. 239 funds tracked by Wall St. Rank hold NKTR as of Q1 2022.

  • Blueshift Asset Management reported no remaining Nektar Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Blueshift Asset Management sold 2,228 Nektar Therapeutics shares in Q1 2022, an estimated $452K.
  • Blueshift Asset Management first reported a position in Nektar Therapeutics in Q4 2021 and held it in 1 quarter.
  • Blueshift Asset Management's Nektar Therapeutics position peaked at $452K in Q4 2021.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2022.

Based on Blueshift Asset Management's 13F filing for Q1 2022, filed 12 May 2022.